Teva Pharmaceutical Industries Limited (TEVA) Shares are Down -1.62%

Teva Pharmaceutical Industries Limited (TEVA) : During the past 4 weeks, traders have been relatively bearish on Teva Pharmaceutical Industries Limited (TEVA), hence the stock is down -3.55% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.58% relative to the S&P 500. The 4-week change in the price of the stock is -3.18% and the stock has fallen -1.62% in the past 1 week.

Teva Pharmaceutical Industries Limited is up 2.02% in the last 3-month period. Year-to-Date the stock performance stands at -18.24%. The stock has recorded a 20-day Moving Average of 1.66% and the 50-Day Moving Average is 0.46%.


Teva Pharmaceutical Industries Limited (NYSE:TEVA): The stock opened at $53.32 on Friday but the bulls could not build on the opening and the stock topped out at $53.59 for the day. The stock traded down to $52.87 during the day, due to lack of any buying support eventually closed down at $52.99 with a loss of -0.11% for the day. The stock had closed at $53.05 on the previous day. The total traded volume was 3,548,116 shares.

Also, HSBC upgrades its rating on Teva Pharmaceutical Industries Limited (NYSE:TEVA). Analysts at the HSBC have a current rating of Buy on the shares. The shares were previously rated Hold. The rating by the firm was issued on July 18, 2016.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.